Hepatitis C virus (HCV) is a viral pandemic, infecting more than 170 million people worldwide (1 ) . Several methods of detecting HCV, such as ELISA, the line immunobinding assay (LIBA), the recombinant immunoblot assay, and PCR are currently being used in HCV diagnosis (2) (3) (4) . Because it is quick, inexpensive, and automated, ELISA is the main method used in hospitals for HCV diagnosis. However, because this ELISA can yield false HCV-positive (5 ) or HCVnegative results under certain conditions, such as in immune-compromised persons (1 ) , data obtained with the ELISA must be confirmed with complicated secondary tests, such as the LIBA or PCR-based protocols (6, 7 ) .
The development of protein chip or microarray technology has provided a highly sensitive, highthroughput method for disease diagnosis (8, 9 ) by facilitating detection-in small amounts of patient samples-of antibodies to antigens from infectious viruses or bacteria (10, 11 ) . However, the current major challenge for the advancement of protein microarray technology is the need for optimized microarray materials that maintain the native conformation of the embedded antigen or antibody (12 ) . In addition, to compete with more standard protocols (e.g., ELISA), the support materials for a protein microarray-based assay must be easy to handle and store and suitable for rapid and inexpensive production in large quantities; furthermore, the assay must yield high-quality, reproducible results (13, 14 ) . The immobilization of proteins within sol-gel-derived materials is an intriguing possibility for use with protein microarrays, because these materials do not require affinity-captured agents or tagged recombinant proteins, thus enabling the size entrapment of a wide variety of proteins in their native states (15 ) . Previously, we developed a novel method for the screening of sol-gel materials that is optimal for protein microarray applications (16 ) . We demonstrated the highly sensitive detection of antigenantibody binding and other protein-protein interactions on protein microarrays derived from our novel sol-gel formulation (16 ) .
Using our optimized sol-gel materials [25.5% tetramethoxysilane, 12.5% tetraethoxysilane, 5.0% PEG8000, 10 mmol/L HCl, and 10 mmol/L sodium phosphate (pH 7. LG Life Sciences), a positive control (Cy3-labeled goat antibody, Abchem), a sol-gel material spot that contained no proteins (the negative control), and an additional unrelated control protein (HIV P24, Abchem) were mixed individually with the optimized sol formulation described in (16 ) , spotted in triplet onto the 96-well plates, and encapsulated within the matrix of the sol-gel nanoporous structures (Fig. 1) . This set of prototypes contained only markers for HCV plus one additional unrelated control protein (HIV P24), which allowed us to test the specificity of our system. We used the HCV core, NS3, NS5, and E1/E2 antigens in our protein microarray assay to allow a better comparison between our protein microarray assay results and that of the existing confirmatory test (LG HCD Confirm, LGLS), which uses the same HCV core, NS3, NS5, and E1/E2 antigens.
We obtained 87 serum samples from HCVpositive patients and 67 serum samples from HCVnegative patients (a total of 154 samples) in whom HCV was detected by means of an HCV EIA 3.0 ELISA assay (Abbott) at Korea University Hospital. All sample donors gave informed consent. Among the 87 samples that were HCV positive according to the ELISA tests, 15 were shown to be false positives according to the LIBA-based confirmatory test (LG HCD Confirm). To avoid complications in interpreting our results, such as those that arise in patients who are immunocompromised by other viruses, we used samples from patients who were infected only with HCV and not with HIV or HBV. We applied these 154 samples to each of the wells of our prototype protein microarrays and then attempted to diagnose hepatitis in a format compatible with the current automated ELISA-based hepatitis diagnostic process. Sera from the HCV-positive and HCV-negative patients and the Cy3-labeled human secondary antibody were incubated for 30 min in the wells, which were then washed using automated ELISA equipment (Fig. 1) . The assay times and conditions that we used were the same as and compatible with the conventional ELISA HCV diagnostic assay, characteristics that should make this new technology more accessible to clinicians (17 ) . After washing, the plate chips were scanned using a 96-well fluorescence laser scanner (FLA-500, Fuji) to measure fluorescence intensity from the Cy3 dye, and the resulting fluorescence intensity of each spot was quantified as an LAU/mm 2 unit using the appropriate software (Multigauge, Fuji). For signal:noise ratios, the signal represented the Cy3 fluorescence intensity from each antigen spot after subtraction of the background fluorescence, and the noise was defined as the Cy3 fluorescence intensity from the negative control spot (without any proteins) after subtraction of the background fluorescence. The cutoff value for HCV-positive samples was determined if Ͼ2 of 4 antigen spots yielded twice as much fluorescent signal (signal) as the negative control spot (noise) (a signal:noise ratio Ͼ2) (see Supplementary Fig. 1 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/ content/vol54/issue2 for cutoff values and distribution of the signal:noise ratios for 154 samples).
We compared HCV diagnosis results obtained using our protein microarrays with those from the conventional ELISA assay. Fig. 1 shows representative results. Our microarray assay showed that 3 of the samples (#1, #2, and #3) were HCV positive because more than 2 of the 4 marker proteins yielded (ϩ) signals. However, positive sample #4 showed only 1 weak (ϩ) signal and thus was considered to be indeterminate in our protein microarray assay. (18 ) . To compare our microarray method with 3 well-accepted confirmatory tests, we measured the sensitivity and specificity of 3 diagnostic methods-the ELISA, the LIBA-based assay, and our protein microarray test-for 13 patient samples. The sensitivity and specificity results (100% and 87.5%, respectively) were identical for the confirmatory and protein microarray assays (see Supplementary Table 2 in the online Data Supplement). Because comparing an HCV RNA-based PCR assay with an anti-HCV-based assay is not practical, we cannot directly compare PCR-based results with those obtained using our protein microarray assays. However, the overall accuracy of our protein microarray method is nearly equivalent or better than that of the LIBA-blot based confirmatory test (19 ) . The inclusion of additional antigens such as NS4 would improve the specificity of this protein microarray-based assay.
To test the detection limit of the protein microarrays, we assayed the chips with serial dilutions of 3 HCV-positive serum samples ( Fig. 1B ; see Supplementary Fig. 2 in the online Data Supplement). Specifically, serum sample #37, which tested positive in the ELISA assay, was diluted up to 10 000 times with HCVnegative serum. Using the sol-gel protein microarray, we were able to detect fluorescent signals with 2 HCV (A), 18 spots including 4 different C-type hepatitis marker proteins were printed (GeneMachine), along with negative controls (no protein) and positive controls (100 ng Cy-3-labeled proteins) on each well of a 96-well plate (16 ) . Schematic diagram (top) indicates spots labeled N (negative controls), P (positive controls), spots numbered 2-5 (HCV markers with 100 ng each of core, NS5, NS3, E1/E2), and spots numbered 1 [P24 protein (HIV P24, Abchem)]. P24 was added as an additional unrelated control protein to test the specificity of the system. Sera from 1 HCV-negative and 4 HCV-positive patients and Cy-3-labeled human secondary antibody were added to the wells. Plates (bottom) show positives #1, #2, and #3, which are true positives. Positive #4, for a sample that was negative in the PCR-based test, is an indeterminate or false positive that was HCV indeterminate with the confirmatory test. The negative sample was from an uninfected patient. A full analysis of the results of these experiments is shown in Table 1 . (B), The detection limit of the HCV diagnosis protein microarrays was determined by serial dilutions of serum from one HCV-positive patient (#37). Core and NS5 signals were plotted along with the positive and negative control results for each diluted sample (top graph). Protein chips detected HCV proteins (Core and NS5) in aliquots of sample #37 that had been diluted up to 1:1000 (bottom image). The negative serum sample (#8) gave no signal even when it was undiluted (bottom image). marker proteins (Core and NS5) when sample #37 was diluted up to 1:1000, whereas the ELISA could detect HCV only in the undiluted HCV-positive sample (#37) (Fig. 1B) . These findings indicate that the protein microarray has a detection limit that is 1000 times that of the ELISA.
We used a sol-gel material optimization method to develop HCV diagnostic microarrays. Successful detection of HCV requires a test with both high sensitivity and high specificity. The sensitivity of the sol-gel protein microarray method is comparable to that of ELISA. With respect to specificity, the sol-gel protein microarray method greatly enhances diagnostic accuracy by decreasing the number of false-positive results. Serum samples with low titer values tend to yield false-positive results in an HCV diagnostic ELISA (see Supplementary Figs. 3 and 4 in the online Data Supplement), whereas with our method, these samples were shown to be HCV negative. Therefore, because of its high throughput, sensitivity, accuracy, and use of economical sol-gel-based techniques, our novel prototype microarray assay shows great potential for replacing the current ELISA-based diagnostic methods (16, 20 ) . In addition, because of the compatibility of our assay with the currently employed automated methods used for ELISA, the existing equipment could be easily adapted for use with our technology. This study is the first clinical application of the sol-gel protein microarray detection system and provides an important new practical screening technology to advance the current state of infectious disease diagnosis. a All experiments were repeated with at least 6 independent plate chips and showed 100% (ϩ)/(Ϫ) cutoff reproducibility (see supplemental Fig. 1 and Table 3 
